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Point mutationWe examined the effect of amino acids 222 and 254 on antigenicity of the variant Del-E strain of infectious
bursal disease virus (IBDV). Using molecular epidemiology, we identiﬁed a virus designated as Del-E-222 that
was identical to Del-E except for alanine at position 222. A second virus was generated using reverse genetics
of the Del-E backbone to create Del-E-254 that contained an asparagine at amino acid 254. The Del-E-222 and
Del-E-254 viruses were tested for their ability to escape neutralizing immunity provided by parenteral
vaccination. The bursas from birds vaccinated with parental Del-E and challenged with Del-E-222 or Del-E-
254 had macroscopic lesions typical of an IBDV infection, and their B-BW ratios were signiﬁcantly smaller
than the controls. Microscopic lesions included lymphocyte depletion and conﬁrmed the ability of Del-E-222
and Del-E-254 to break through the immunity induced by the parental Del-E virus vaccination. Both
mutations appear to be contributing to antigenic drift.nfectious bursal disease virus;
on; B-BW, bursa body weight;
nce region of viral protein 2.
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Infectious bursal disease virus (IBDV) causes an immunosuppres-
sive disease in young chickens by infecting lymphocytes in the bursa
of Fabricius. Infectious bursal disease (IBD) has been recognized as a
signiﬁcant problem in chickens since 1962 (Cosgrove, 1962). Despite
the use of vaccines to control IBDV, it continues, directly and indirectly
via immune suppression, to cause economic losses in the poultry
industry. The magnitude of these economic losses is difﬁcult to
appreciate because the immune suppression caused by IBDV often
goes unnoticed until opportunistic pathogens cause diseases like
gangrenous dermatitis (Rosenberger et al., 1975) or ﬂock vaccination
programs fail (Giambrone et al., 1977).
Antigenic drift in IBDV is thought to be responsible for the
formation of antigenic variant strains of the virus. Two substitution
mutations (D318G and E323D) in the second hydrophilic region of the
hypervariable sequence in VP2 (hvVP2) were necessary for the escape
of the variant Del-E IBDV strain from neutralizing monoclonal
antibodies (Heine et al., 1991). Substitution mutations in the ﬁrst
hydrophilic region of hvVP2 were also observed in that study: D213N
and P222T. These data indicated the two hydrophilic regions are in
close physical approximation to each other and together form a major
neutralizing epitope of the virus, a property of VP2 that was laterconﬁrmed using X-ray crystallography (Coulibaly et al., 2005). These
amino acid mutations in the hydrophilic regions of hvVP2 were also
necessary for the escape of the Del-E variant from neutralizing
antibodies produced by vaccination using a classic IBDV strain (Heine
et al., 1991). Further studies on speciﬁc amino acid mutations that
affect the binding of neutralizing monoclonal antibodies have been
conducted (Eterradossi et al., 1997; Vakharia et al., 1994). These
studies demonstrated that themajor neutralizing epitopes of IBDV are
located in the hypervariable region of VP2 by mapping neutralizing
monoclonal antibodies to speciﬁc regions of the protein. Studies using
reverse genetics have shown that several amino acids in the
projection (P) domains of VP2 are important for reactivity to
neutralizing monoclonal antibodies (Letzel et al., 2007). In this
study, amino acid substitutions in the PBC and PHI loops of VP2 were
shown to inﬂuence the binding of viral neutralizing epitopes to
monoclonal antibodies.
Although amino acids in hvVP2 were shown to be important for
binding and the escape of IBDV from neutralizing monoclonal
antibodies, the contribution of these amino acids to antigenic drift
still needs to be examined in vivo. Our studies identiﬁed IBDV strains
that were capable of breaking through maternal immunity generated
using variant and classic IBDV vaccines (Jackwood et al., 2001).
Sequence analysis of these viruses indicated that in some cases only
one or two amino acids had been substituted (Jackwood and Sommer-
Wagner, 2005). These molecular epidemiologic studies suggest IBDV
has continued tomutate amino acids in hvVP2 that are contributing to
antigenic drift in the virus. Our hypothesis is that a single point
mutation can signiﬁcantly contribute to antigenic drift in the Del-E
variant IBDV and speciﬁc point mutations will allow the virus to
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hypothesis, we identiﬁed a Del-E strain with a single substitution
mutation (T222A) in the ﬁrst hydrophilic hvVP2 region (PBC) and
using reverse genetics generated another Del-E virus with a
substitution mutation (S254N) in the PDE region of hvVP2 that is
between the two major hydrophilic projections PBC and PHI. These
mutant viruses were then tested for their ability to cause disease in
chickens with immunity generated using a Del-E vaccine strain.
Results
Identiﬁcation and production of substitution mutations in Del-E
In a previous study, we identiﬁed an IBDV strain that had an hvVP2
sequence identical to Del-E except for a substitution at position 222
(Jackwood and Sommer-Wagner, 2005). To determine if this was the
only amino acid mutation, we determined the complete nucleotide
sequence of both genome segments from this virus. The nucleotide
sequences of genome segments A and B conﬁrmed that Del-E-222 had
an identical amino acid sequence to Del-E in both genome segments
(AF133904 and AF133905) except for an alanine (A) at position 222 in
VP2 (Fig. 1). This virus was propagated in 9-day-old embryonated
chicken eggs.
The Del-E-254 virus generated using site-directed mutagenesis
was also identical to Del-E except for an asparagine (N) at position
254 in VP2 (Fig. 1). This virus also produced lesions typical of a Del-E
infection when inoculated into 9-day-old embryonated chicken eggs
(data not shown).
Vaccination/challenge experiments
Although the Del-E strain is pathogenic in SPF chickens, the
virulence of Del-E-222 and Del-E-254 needed to be tested. Birds that
were not vaccinated but were challengedwith Del-E (Group 3), Del-E-
222 (Group 5), or Del-E-254 (Group 7) had small friable bursas. Gross
lesions in these bursas were typical for variant strains in the acute and
chronic phase of the disease. The B-BW ratios calculated for these
groups were signiﬁcantly smaller (p≤0.05) than the controls in
Group 1 (Table 3). Microscopic lesions in the bursa tissues consisted of
moderate depletion of lymphocytes, variable loss of follicles, and
reticuloendothelial cell proliferation with lymphocyte necrosis. The
histopathologic lesion score for Del-E was 2, while a score of 3 was
observed for both Del-E-222 and Del-E-254 (Table 3). These
histopathologic lesion scores were subjective and may not represent
increased virulence in the Del-E-222 and Del-E-254 viruses compared
to the parental Del-E strain.
Antibodies to IBDV were not detected in serum samples collected
from SPF birds at hatch and prior to vaccination on day 10 using the
virus neutralization and ELISA procedures. Neutralizing antibodies
were detected at challenge in birds vaccinated with the homologous
89/03 vaccine. These neutralizing antibody titers ranged from 200 to
800 with a geometric mean of 264 (Table 2). The ELISA titers in
vaccinated birds prior to challenge ranged from 77 to 701 with a
geometric mean of 125 (Table 2). At 7 days following challenge,
relatively high virus-neutralizing and ELISA titers were observed in all
the challenged groups (Table 2). No antibodies to IBDV were detected
in the un-vaccinated/non-challenged birds in Group 1.Fig. 1. Partial amino acid sequences of the hvVP2 region showing substitution mutations of
genome segment B sequences of all four viruses are identical to the Del-E virus (AF133905At 7 days following challenge, birds in Group 4 that were vaccinated
with 89/03 and challenged with the homologous Del-E virus did not
have signs of macroscopic or microscopic lesions in the bursa (Table 3).
However, birds that had been vaccinated with 89/03 and then
challenged with Del-E-222 or Del-E-254 had gross lesions in the bursa
that were similar to the Group 3 un-vaccinated/Del-E challenged
controls. In addition, their B-BW ratios were similar to those observed
when these challenge viruseswere used in un-vaccinated birds (Groups
5 and 7) (Table 3).Microscopic lesionswere also similar to those seen in
Groups 5 and 7 although they appeared to be slightly less severe and
received histopathologic lesion scores of 2 (Table 3).
Comparative viral loads following challenge
A real-time RT-PCR assay was used to determine the relative viral
loads in bursa tissue following challenge. This assay was originally
developed to differentiate very virulent IBDV from endemic IBDV in
the United States (Jackwood et al., 2009). The efﬁciency reported for
the assay in detecting endemic IBDV that includes the variant Del-E
strain was 99.96% (R2=0.999). The mean cycle threshold (Ct) values
were determined for 4 replicates of each sample (Table 3). No
signiﬁcant differences (pN0.05) were observed between the mean Ct
values for Groups 5, 6, 7, and 8. The mean Ct value of the vaccinated
group was subtracted from the mean Ct value of the non-vaccinated
group to achieve aΔCt. TheΔCt for the Del-E-222 challenged Groups 5
and 6 was −0.25. An identical ΔCt was observed for the Del-E-254
challenged Groups 7 and 8. These ΔCt values were less than one
standard deviation observed for the individual Ct values and indicate
no difference in viral load between the vaccinated and unvaccinated
groups.
Discussion
Antigenic drift in the Birnavirus IBDV has been attributed to
substitution mutations in the hypervariable sequence region of the
capsid protein VP2 (Heine et al., 1991). Much is known about the
mutations that occur in the hvVP2 region (Van Den Berg et al., 2000)
and the three-dimensional structure of the VP2 viral protein
(Coulibaly et al., 2005). Studies have also been conducted on the
speciﬁc substitutions needed to signiﬁcantly alter the antigenic
property of the virus (Letzel et al., 2007; Eterradossi et al., 1997,
1998; Vakharia et al., 1994). These studies used neutralizing
monoclonal antibodies to assess antigenic changes that were the
result of substitution mutations in VP2. To our knowledge, this is the
ﬁrst report where the antigenic property of IBDV was assessed in vivo
following single substitution mutations in the hvVP2 region.
Variant Del-E viruses with single point mutations at amino acids
T222A and S254N in VP2 were identiﬁed and tested for antigenic drift
in SPF layer chickens. These mutations were selected because they
were observed in viruses that caused disease in commercial chicken
ﬂocks with immunity to variant IBDV strains (Jackwood and Sommer-
Wagner, 2005). Since these substitution mutations were based on
sequence analysis of viruses causing disease in the ﬁeld and not on
escape from neutralizing monoclonal antibodies, it is likely that they
are pragmatically contributing to antigenic drift in these viruses. The
222 and 254 amino acids are located at the tips of the loop structures
in VP2. The T222A mutation is located in the ﬁrst hydrophilic
projection loop PBC, and substitution mutation S254N is located in
Loop PDE, which is between the two major hydrophilic projectionsviruses Del-E-222 and Del-E-254 compared to the parent Del-E (AF133904) strain. The
).
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hydrophilic projections (Loops PBC and PHI) have been extensively
studied, few studies on antigenicity have examined substitutions in
the minor hydrophilic loop PDE (Vakharia et al., 1994). Our molecular
epidemiology data suggest loop PDE may be important in the antigenic
drift of variant IBDV strains because mutations at position 254 were
frequently observed in viruses that could break through maternal
immunity to IBDV (Jackwood and Sommer-Wagner, 2005; Jackwood
et al., 1997).
In the present study, the data indicate the T222A and S254N point
mutations created a measurable antigenic change in Del-E that was
detected in this controlled vaccination/challenge study. The Del-E
vaccine 89/03 was administered according to the manufacturer's
instructions and induced neutralizing and ELISA antibody titers to the
virus. At the time of challenge, these titers were relatively low, but it
has been shown that humoral and cellular immunity are important in
protection against IBDV infections (Rautenschlein et al., 2002).We did
not measure the cellular immune response to the 89/03 vaccine, but it
is clear that the immunity induced by this vaccine protected the SPF
chickens from disease following challenge with an antigenically
homologous and virulent Del-E virus. Immunity to the 89/03 vaccine
also appears to have appreciably affected infection since we were
unable to detect RNA from the homologous Del-E challenge virus in
the bursa of vaccinated birds. We were able to detect the Del-E-222
and Del-E-254 following challenge of 89/03 vaccinated birds using
this real-time RT-PCR assay. The relative quantities of each of these
challenge viruses were determined between the non-treated group
(unvaccinated) and treated group (vaccinated) using a comparative
Ct method. The ΔCt values indicated that immunity induced by
vaccination with the Del-E 89/03 virus did not signiﬁcantly alter the
quantity of Del-E-222 and Del-E-254 challenge viruses detected in the
bursa.
The variant IBDV including Del-E typically produces a bursa lesion
score in the range of 2-3 in susceptible SPF chicks (Perozo et al., 2009).
Although the bursa lesion score is a subjective measure, the strength
of the challenge for all three viruses (Del-E, Del-E-222, and Del-E-254)
appeared to be similar. Although this may be considered a weak
challenge compared to classic and very virulent IBDV strains, too
strong a challenge could overwhelm the immunity produced by the
vaccine and thus produce false positive data. The fact that a weak
challenge was still capable of breaking through the vaccine induced
immunity is strong evidence that the amino acid mutations at
positions 222 and 254 in VP2 were contributing to antigenic drift.
The results support our hypothesis that a single pointmutation can
signiﬁcantly contribute to antigenic drift in IBDV. Although the 222
and 254 amino acid positions in hvVP2 appear to be important for
antigenic drift in Del-E variant viruses, it is possible that substituting
different amino acids at these sites would not have signiﬁcantly
altered antigenicity. Furthermore, monoclonal antibody studies
suggest the 222 and 254 amino acid sites are not the only two that
may be contributing to antigenic drift (Eterradossi et al., 1997; Letzel
et al., 2007; Vakharia et al., 1994). Nevertheless, these studies
contribute to our understanding of the amino acids that cause
antigenic drift in vivo and the ability of IBDV to evade immunologic
control efforts used in the poultry industry.
The S→Nmutation at 254 was produced using reverse genetics in
this study, and although we have observedmany Del-E variant strains
of IBDV with this mutation, all have substitutions in at least one other
site in hvVP2 (Jackwood and Sommer-Wagner, 2005). Thus, we were
unable to study the contribution of the 254 site to antigenicity using a
naturally occurring mutant of the Del-E variant virus. The T→A
mutation at amino acid 222 has only been observed in a few variant
strains of IBDV, but alanine at this position is a common substitution
in the very virulent (vv) IBDV strains. Finding this single point
mutation in a naturally occurring Del-E variant is important not only
because it can signiﬁcantly alter antigenicity but also because it mayrepresent a new class of variant viruses that appear to be breaking
through maternal immunity to the Del-E type variant vaccines.
Epidemiological studies are needed to determine if the A222 mutant
virus is becoming widespread and replacing Del-E strains in the
United States. The spread of this virus may be affected by classic virus
vaccines. Classic vaccines have been shown to be efﬁcacious against
vvIBDV strains, which are A222 viruses (Van Den Berg and Meule-
mans, 1991), but other amino acid differences in the hvVP2 region of
the variant A222 viruses may circumvent the utility of these classic
vaccines. Studies to determine if a classic virus vaccine would protect
against the A222 variant viruses are needed.
Materials and methods
Viruses
The variant Del-E strain was used for the production of full-length
clones and reverse genetic experiments. The Del-E vaccine strain-
designated 89/03 (Intervet, Schering-Plough Animal Health, Millsboro,
DE) has an identical amino acid sequence to the variant Del-E except for
two mutations in VP2 that contribute to attenuation and allow
replication in cell culture; histidine at position 253 and threonine at
position 284 (Brandt et al., 2001;Mundt, 1999). Thesemutations do not
appear to affect antigenicity as 89/03 is widely used in the poultry
industry to successfully vaccinate against the virulent Del-E strain
(Intervet, Schering-Plough Animal Health) (Rosenberger, 1986). The
BGM-70 cell line is used routinely in our laboratory to isolate and
propagate IBDV strains (Dahling and Wright, 1986). The 89/03 vaccine
strain of Del-E was propagated in BGM-70 cells.
The Del-E-222 virus was identiﬁed using molecular epidemiology
and had an identical sequence in both genome segments to Del-E
(AF133904 and AF133905) except for the T→A mutation at position
222 in genome segment A (Fig. 1) (Jackwood and Sommer-Wagner,
2005). This virus was propagated in 9-day-old embryonated chicken
eggs inoculated via the chorioallantoic membrane using standard
procedures (Jackwood et al., 2009). Lesions typical of a Del-E infection
were observed in the embryos 7 days following inoculation.
The Del-E-254 virus was generated using reverse genetics and had
an identical amino acid sequence to Del-E except for a substitution
mutation S→N at amino acid position 254. Following the rescue of
this virus and propagation in 4-week-old SPF chickens, the titer was
determined by inoculating the chorioallantoic membrane of 9-day-
old embryonated chicken eggs (Jackwood et al., 2009).
Reverse genetics
The full-length genome segments A and B fromDel-Ewere prepared
using RT-PCR (Mundt and Vakharia, 1996). The forward primers
contained the T7 promoter region and an EcoRI sequence (Table 1).
The full-length products were ligated into pCR-XL-TOPO (Invitrogen
Corp., Carlsbad, CA), and the products were used to transform DH5α
Escherichia coli. Transformed bacteriawere grown on LB agar containing
50 μg/ml kanamycin.
The GeneTailor site-directed mutagenesis system (Invitrogen
Corp.) andmutation primers (Table 1) were used to create a mutation
at amino acid 254 in genome segment A. Themutant full-length cDNA
of genome segment A and the full-length genome segment B cDNA
were sequenced (University of Wisconsin biotechnology Center DNA
Sequence Facility, Madison, WI) and analyzed using our standard
procedures (Jackwood et al., 2008). These cDNAs were excised from
the plasmids using EcoRI and used in a transcription reaction that
employed the T7 promoter (Invitrogen Corp.). The segment A and B
RNA transcripts were combined and prepared for transfection into
BGM-70 cells (Dahling and Wright, 1986) using the Lipofectamine
2000 reagent (Invitrogen Corp.). Brieﬂy, the transcripts were added to
50 μl of Opti-MEM I medium (Invitrogen Corp.) and in a separate tube
Table 1
Primers used in site-directed mutagenesis and to amplify genome segments A and B.
Primersa Primer Sequences 5′–3′
S254N site-directed
mutant—forward
GTTCAAAACAAGCGTCCAAAaCCTTGTACTGG
S254N site-directed
mutant—reverse
TGGACGCTTGTTTTGAACACGAGCTCTC
Full-length segment
A—forward
AGAGAATTCTAATACGACTCACTATAGGATACGATGGGTCTGAC
Full-length segment
A—reverse
AGGGGACCCGCGAACGGATCC
Full-length segment
B—forward
AGAGAATTCTAATACGACTCACTATAGGATACGATGGGTCTGACC
Full-length segment
B—reverse
GGGGGCCCCCGCAGGCG
a The overlapping sequences of the site-directed mutagenesis primers are under-
lined, and the mutation is shown in lower case. For the full-length primers, the EcoRI
site is in bold, the T7 promoter sequences are in italics, and the IBDV-speciﬁc sequences
are underlined. The IBDV-speciﬁc sequences of the full-length primers were similar to
those previously published (Jackwood et al., 2008), and the forward full-length primers
were modiﬁed according to Mundt and Vakharia (1996).
Table 2
Antibody titers to IBDV in SPF chickens a.
Group Treatment vaccine/challengeb Virus neutralizationc ELISAd
1 Control b100 b50
2 89/03/None 264 125
3 None/Del-E 3763 7769
4 89/03/Del-E 4081 8428
5 None/Del-E-222 4579 7852
6 89/03/Del-E-222 5571 6046
7 None/Del-E-254 8163 6646
8 89/03/Del-E-254 4688 3878
aBirds were vaccinated at 10 days of age and challenged at 21 days of age.
b Serum samples were collected prior to challenge on day 21 in Groups 1 and 2 and at
7 days post-challenge in Groups 3, 4, 5, 6, 7 and 8.
c Virus neutralization titers are the geometric means of 5 samples.
d The IBD-XR ELISA (IDEXX, Corp.) was used to assay the sera. Each serum sample was
tested in duplicate. Each titer represents the geometric mean of 5 samples.
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medium. After 5 min at room temperature, the mixtures were
combined and incubation at room temperature continued for
20 min. Following the addition of the Lipofectamine/RNA transcript
mixture to the BGM-70 cells, they were incubated at 37 C for 48 h. The
transfected cells were then frozen and thawed 3 times before being
used to inoculate 4-week-old SPF chickens via the oral/nasal route. At
day 4 post-inoculation, the birds were euthanized and bursa tissues
were collected. These tissues were examined for the presence of virus
using our standard RT-PCR ampliﬁcation of the hvVP2 region and
nucleotide sequencing procedures (Jackwood et al., 2008). To identify
the desired S254N substitution and conﬁrm that no other mutations
had occurred, the full-length genome segment A and the full-length
genome segment B were ampliﬁed using RT-PCR and sequenced
(University of Wisconsin biotechnology Center DNA Sequence
Facility, Madison, WI) (Jackwood et al., 2008).
Vaccination/challenge experiments
These experiments were conducted to examine if a measurable
antigenic drift had occurred as a result of a single mutation in VP2.
Ten-day-old SPF chickens were randomly assigned to eight groups
containing 5 birds each; Group 1, non-vaccinated, non-challenged
control; Group 2, 89/03 vaccinated, non-challenged control; Group 3,
non-vaccinated, Del-E challenged; Group 4, 89/03 vaccinated, Del-E
challenged; Group 5, non-vaccinated, Del-E-222 challenged; Group 6,
89/03 vaccinated, Del-E-222 challenged; Group 7, non-vaccinated,
Del-E-254 challenged; Group 8, 89/03 vaccinated, Del-E-254 chal-
lenged (Tables 2 and 3).
Vaccination
A live-attenuated Del-E vaccine designated 89/03 (Intervet, USA)
was used to vaccinate 10-day-old SPF chickens in Groups 2, 4, 6, and
8 (Table 3). Each bird was given a single dose/bird orally according to
the manufacturer's instructions (Intervet, USA).
Challenge
Birds in Groups 3 and 4 were inoculated with the Del-E virus
(Table 3). Birds in Groups 5 and 6 were challenged with the Del-E-222
virus and birds in Groups 7 and 8 were challenged with the Del-E-254
virus (Table 3). The challenge viruses were administered orally at a
103.0 50% mean egg infectious dose (EID50)/bird. At 7 days following
challenge, all birds were euthanized and examined for macroscopic
and microscopic signs of disease. Body and bursa weights were
recorded and bursa/body weight (B/BW) ratios were calculated.Histopathology
Bursa tissues were collected at necropsy and placed in 10% neutral
phosphate-buffered formalin. The ﬁxed tissues were sectioned at
4 μm and stained using hematoxylin and eosin. They were examined
using light microscopy and graded based on the extent of lymphocyte
necrosis, follicular depletion, and atrophy. Scores of 0 to 4 were used
to indicate relative degree of severity, a score of “0”indicated absence
of lesions, and scores 1 to 4 were forb25%, 25–50%, 50–75%, and N75%
of the follicles affected, respectively.
Quantitative real-time RT-PCR
To determine viral load in the bursa tissue of IBDV challenged
chicks, a relative real-time RT-PCR assay was conducted (Crossley et
al., 2009). Following challenge, 0.1 g of each bursa from a treatment
group was pooled, homogenized in 1.0 ml TNE buffer (10 mM Tris–
HCl, pH 8.0, 100 mM NaCl, 1 mM ethylene diamine tetra acetic acid)
and an 800 μl volume was extracted to obtain RNA using a standard
Trizol procedure (Invitrogen, Corp. Carlsbad, CA). The RNA extracted
from each tissue pool was placed in a 50 μl volume of 90% DMSO in
sterile water, and 1.0 μl was used for each real-time RT-PCR assay. A
743 bp region of the hypervariable sequence region of VP2 (hvVP2)
was ampliﬁed using primers 743-1: 5′-GCCCAGAGTCTACACCAT-3′
and 743-2: 5′-CCCGGATTATGTCTTTGA-3′. The ampliﬁed products
were identiﬁed using a TaqMan probe designed for the challenge virus
(VIC-5′-CTGTTCTCAGCCAACATTGATGC-3′) (Applied Biosystems, Cus-
tomOligo Synthesis Service, Foster City, CA). A real-time RT-PCR assay
kit (AgPath-ID, Ambion, Inc., Austin, TX)was used. The RTwas at 48 °C
for 10 min followed by a 95 °C denaturation for 10 min. Forty cycles of
PCR were conducted in a two-step reaction at 95 °C for 15 s and 58 °C
for 90 s. Total reaction volumes were 25 μl, and the assays were
conducted in a Roche LightCycler 480 instrument (Roche Diagnostics
Corp., Indianapolis, IN). Relative quantities of challenge virus in the
bursa tissues were determined using a comparative Ct method. Four
extractions of each sample were tested in the assay and the ΔCt was
determined by subtracting the mean Ct of the non-treated (unvac-
cinated control) samples from the mean Ct of the treated (vaccinated)
samples for a given challenge virus.
Serology
Sera from blood samples collected at necropsy were examined for
antibodies to IBDV using the IBD-xr ELISA kit (IDEXX, Inc. Westbrook,
ME) according to the manufacturer's instructions. The sera were also
tested in an in vitro virus neutralization assay previously described
(Dybing and Jackwood, 1998). The assay was conducted in BGM-70
cells grown in 96-well tissue culture plates (Falcon, Becton Dickinson
Labware, Franklin Lakes, NJ). The 89/03 vaccine virus was used as
antigen. Sera were diluted twofold and tested against 100 median
tissue culture infectious doses (TCID50) of virus. Neutralizing antibody
Table 3
Mean bursa body weight (B-BW) ratios and the bursal histopathology scores for SPF chickens following challenge a.
Group 89/03 Vaccinated Del-E challenge Del -E-222 challenge Del-E-254 challenge Mean bursa/body weight±SDb Histopathologic lesion scorec Mean Ct±SDd
1 − − − − 5.58±1.16e 1,0,0,0,0 Neg
2 + − − − 5.49±0.91e 0,0,0,1,0 Neg
3 − + − − 2.72±0.78f 2,2,3,2,2 31.75±0.97
4 + + − − 4.82±0.92e 0,1,0,0,1 Neg
5 − − + − 1.82±0.59f 2,3,3,4,3 31.75±1.71
6 + − + − 1.90±0.48f 2,2,2,2,3 32.00±1.41
7 − − − + 1.62±0.24f 2,3,4,2,3 31.25±0.50
8 + − − + 2.14±0.31f 2,3,3,2,2 31.50±0.58
a Speciﬁc-pathogen-free chickens were vaccinated with the Del-E attenuated strain 89/03 at 10 days of age. Each bird received 103.0 EID50 in 0.1 ml orally. At 21 days of age (11 days
post-vaccination), birds were challenged with Del-E, Del-E-222, or Del-E-254. Each bird challenged received 103.0 EID50 in 0.1 ml orally.
b The mean B-BW ratios±standard deviations for 5 samples were calculated. Mean B-BW ratios=bursa wt. (g)/body wt (g)×1000. Different superscript letters indicate statistically
signiﬁcant differences among the group means (p≤0.05).
c The severity of the microscopic lesions was graded based on the extent of the lymphocyte necrosis, follicular depletion, and atrophy. Scores of 0 to 4 were used to indicate relative
degree of severity, a score of ‘0'indicated absence of lesions, and scores 1 to 4 were for b25%, 25 to 50%, 50 to 75%, and N75% of follicles affected, respectively. Individual scores for each
of the ﬁve birds examined are reported.
d The mean cycle threshold (Ct) values±standard deviation were used to determine relative vial load. Four replicates of each sample were tested in the real-time RT-PCR assay.
Neg=real-time RT-PCR was negative.
37D.J. Jackwood, S.E. Sommer-Wagner / Virology 409 (2011) 33–37titers were reported as the geometric mean of the last dilution that
neutralized 50% of the replicates.
Statistical analysis
The B/BW ratios were compared by ANOVA and Fisher's least
squares test for differences among groups.
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